- ￥108 - 638.50
- TargetMol
- USA
- T0101
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
RT
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -124℃ for several months.
- 英文名：
Doxazosin mesylate
- 库存：
详询
- 供应商：
详询
- CAS号：
77883-43-3
- 规格：
2mg/10mg/50mg/1ml/10mM
| 规格： | 2mg | 产品价格： | ￥108.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥248.0 |
| 规格： | 50mg | 产品价格： | ￥638.5 |
| 规格： | 1ml/10mM | 产品价格： | ￥448.0 |
ID：T0101
PURITY：0.98
Formula：C24H29N5O8S
MolWt：547.58
Appearance：白色粉末
Solubility：G4Freely soluble in DMSO
Bioactivity：Doxazosin Mesylate is a selective, long-lasting antagonist of α1-adrenergic receptor. Doxazosin Mesylate has been reported to potentiate contraction response to 5-HT in a dose-dependent manner. Doxazosin significantly reduced alcohol drinking and increased water intake in adult male P rats.Studies has indicated that doxazosin could inhibit TNF-α expression in LPS-induced systemic inflammation model as well as reduce the MCP-1 production in LPS-induced pulmonary inflammation model. Additionally, Doxazosin decreased thickness of footpad in the delayed-type hypersensitivity mice model. Doxazosin had been reported to slightly reduce MCP-1 level in the peritoneal cavity of mice induced by thioglycollate.
Status：USAN, INN, BAN, JAN
Pathways：GPCR/G Protein
Target：Adrenergic Receptor agonist
Receptor：Adrenergic Receptor
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase
-4 and C-5 centers ( 3 ). After formatron of the mesylate, from the recycled material the amine function is introduced through azrde displacement of the mesylate, followed by reduction ( 4 ) and protectron with the t -BOC group. Finally, the lactone
Inhibitors of Cellular Signaling Targets: Designs and Limitations
. Because of their central role in cellular signaling, as well as their primary role in disease progression, protein kinases are attractive therapeutic targets (2 ,3 ). Seven molecules targeting protein kinases, imatinib mesylate (Gleevec) and trastuzumab (Herceptin
技术资料暂无技术资料 索取技术资料
